Fast acting naratriptan composition
View Patent ↗The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient.
1. A pharmaceutical composition comprising:
(a) naratriptan or a salt thereof,
(b) at least one compound selected from 8-(2-hydroxyphenoxy)octyldiethanolamine, 6-(2-hydroxyphenoxy)hexylmorpholine, 2-(4-phenoxyphenyl)ethyldiethanolamine, 2-(biphen-4-yl)ethyldiethanolamine, and pharmaceutically acceptable salts thereof; and
(c) optionally, a pharmaceutically acceptable excipient,
wherein the pharmaceutical composition, when administered orally, has a shortened time for the onset of maximum peak concentration (T max ) compared to naratriptan alone.
2. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises a naratriptan salt.
3. The pharmaceutical composition of claim 2 , wherein said naratriptan salt is selected from a hydrochloride, hydrobromide, mesylate, acetate, trifluoroacetate, propionate, fumarate, tartrate, citrate, phosphate, succinate, bisulfate, or besylate salt.
4. The pharmaceutical composition of claim 1 , wherein said compound is 8-(2-hydroxyphenoxy)octyldiethanolamine.
5. The pharmaceutical composition of claim 1 , wherein said compound is 6-(2-hydroxyphenoxy)hexylmorpholine.
6. The pharmaceutical composition of claim 1 , wherein said compound is 2-(4-phenoxyphenyl)ethyldiethanolamine.
7. The pharmaceutical composition of claim 1 , wherein said compound is 2-(biphen-4-yl)ethyldiethanolamine.
8. The pharmaceutical composition of claim 1 , wherein said naratriptan or a salt thereof, and said compound are present in a ratio from about 1:100 to about 1:5.
9. A method of treating migraine headaches, comprising orally administering a pharmaceutical composition of claim 1 to a subject in need thereof.
10. The method of claim 9 , wherein said pharmaceutical composition, upon oral administration, takes at least 40% less time to reach T max in comparison to administering naratriptan alone.
11. The method of claim 9 , wherein said pharmaceutical composition, upon oral administration, takes at least 50% less time to reach T max in comparison to administering naratriptan alone.
12. The method of claim 9 , wherein said pharmaceutical composition, upon oral administration, takes at least 60% less time to reach T max in comparison to administering naratriptan alone.
13. The method of claim 9 , wherein said pharmaceutical composition, upon oral 5 administration, takes at least 70% less time to reach T max in comparison to administering naratriptan alone.
14. The method of claim 9 , wherein said pharmaceutical composition, upon oral administration, takes at least 75% less time to reach T max in comparison to administering naratriptan alone.
15. The method of claim 9 , wherein said pharmaceutical composition, upon oral administration, lakes at least 80% less time to reach T max in comparison to administering naratriptan alone.
16. The method of claim 9 , wherein the pharmaceutical composition, upon oral administration, takes at least 20% less time to reach T max in comparison to administering naratriptan alone.
17. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, takes at least 20% less time to reach T max in comparison to administering naratriptan alone.
18. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, takes at least 40% less time to reach T max in comparison to administering naratriptan alone.
19. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, takes at least 50% less time to reach T max in comparison to administering naratriptan alone.
20. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral 5 administration, takes at least 60% less time to reach T max in comparison to administering naratriptan alone.
21. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, takes at least 70% less time to reach T max in comparison to administering naratriptan alone.
22. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, lakes at least 75% less time to reach T max in comparison to administering naratriptan alone.
23. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition, upon oral administration, lakes at least 80% less time to reach T max in comparison to administering naratriptan alone.